Novartis South Africa (Pty) Ltd v Maphil Trading (Pty) Ltd

Novartis South Africa, through its Sandoz Specialty Division (SSD), sought to promote its brand following regulatory changes that restricted pharmaceutical marketing. SSD representatives negotiated with Hiline Medical (later Maphil Trading) for Hiline to place Sandoz branding on medical device packaging supplied to hospitals. On 14 October 2004 SSD presented a partly written marketing agreement offering a R3.5 million annual marketing fee. The detailed marketing activities were to be finalised by 30 November 2004. The parties thereafter agreed on the marketing activities through meetings, telephone discussions and email exchanges, and both acted as if bound by the agreement. Hiline reduced prices in a major tender in reliance on SSD’s commitment. In March 2005 Novartis denied the existence of a binding contract and refused to pay, leading Hiline/Maphil to sue for damages for repudiation.

The appeal was dismissed with costs, including the costs of two counsel where employed.

The case is significant for confirming that a binding contract under South African law may be concluded through a combination of written documents, oral agreements and email correspondence. It reinforces the contextual and purposive approach to contractual interpretation endorsed in Endumeni and subsequent cases, and cautions against overly formalistic or literal approaches that undermine commercial reality.